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Background: Large intracranial occlusive vascular disease is a major contributor to the incidence of stroke
worldwide, especially when it involves the middle cerebral artery (MCA). The data on the prognosis of symptomatic
atherosclerotic MCA occlusions (MCAO) with concomitant intracranial arterial disease (MCAO-AIS) are limited.
MCAO-AIS may reflect the extent of the atherosclerotic intracranial disease, we hypotheses that coexisting intracranial
arterial disease influenced the prognosis of MCAO.
Methods: Patients having survived at least one month after the initial ischemic stroke who suffered from
atherosclerotic occlusion of the MCA were enrolled. According to their concomitant atherosclerotic intracranial arterial
disease, the patients were assigned to one of two groups: the MCAO or the MCAO-AIS. All of the patients’ cerebrovascular
risk factors were recorded. Recurrent ischemic stroke and death were the end-point events during the follow-up.
Results: A total of 232 patients (mean age 57.68 ± 9.50 years; 69% male) were analyzed. The mean follow-up time was
17.65 months. The end-point events occurred in 35 (15.09%) patients, resulting in an annual rate of 10.26%. The presence
of MCAO- AIS was an independent risk factor associated with the patient’s prognosis in the cohort (OR = 3.426, 95% CI
1.261 to 9.308; p = 0.016), as well as gender and diabetes mellitus. The MCAO-AIS were more likely to experience
ipsilateral ischemic strokes, but the difference was not statistically significant.
Conclusion: Concomitant intracranial arterial disease may influence the prognosis of patients with atherosclerotic
MCAO. The result warrants further research in larger sample population.
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Intracranial atherosclerotic occlusion or stenosis is an
important cause of ischemic stroke in both Asians and
African Americans [1-3]. The middle cerebral artery
(MCA) is one of the most common sites involved in
symptomatic intracranial atherosclerosis. Previous studies
have reported that the annual risk of stroke in patients
with symptomatic MCA stenosis is 4% ~ 15% [4-7]. Al-
though the prognosis of patients with symptomatic and
asymptomatic MCA stenosis has been studied previously,
few studies have reported data on patients with a middle
cerebral artery occlusion (MCAO). Furthermore, the* Correspondence: xfliu2@vip.163.com
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unless otherwise stated.previous studies have reported that the recurrence of
stroke in patients with MCAO did not differ from stroke
recurrence with severe MCA stenosis [5,6,8,9]. These
studies included a very small number of patients. There-
fore, greater knowledge of the natural course or cere-
brovascular events of MCAO disease is need, especially
considering its few treatment options.
Previous studies have reported that diabetes mellitus,
stroke symptoms, and gender may influence the prognosis
of patients with symptomatic MCAO [7,9,10]. However,
there is little in the literature on MCAO with concomitant
intracranial arterial disease (MCAO-AIS). The rate of
MCAO-AIS in patients with symptomatic stenosis is high,
approximately 18.9% to 27.3% [11]. MCAO-AIS may sug-
gest a generalized atherosclerotic process, which may por-
tend a poor prognosis [12]. The number of coexistingis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tent of the atherosclerotic intracranial disease. Considering
the points above, we hypothesized that coexisting AIS
may influenced the prognosis of patients with symptom-
atic MCAO.
We therefore conducted this retrospective analysis to
evaluate the further progression of MCAO-AIS and its




We consecutively recruited patients who were admitted to
our hospital and had cerebral angiographic records from
January 2006 to January 2010. The data were documented
prospectively in the Nanjing Stroke Registry Program. Pa-
tients were included if they met the following criteria: 1)
occlusion in the M1 segment of the MCA that was proven
by magnetic resonance angiography (MRA) or cerebral
digital subtraction angiography (DSA), 2) an initial ische-
mic stroke or transient ischemic stroke (TIA) within the
occluded MCA distribution territory, 3) at least one risk
factor of atherosclerosis, 4) survival for at least one month
after the onset, and 5) an age greater than 40 years old.
We excluded: 1) patients with a history of stroke or
TIA, 2) those who died during one month after the one
of symptoms, 3) patients with atrial fibrillation (AF)
which included chronic or paroxysmal AF. Paroxysmal
atrial fibrillation was defined as episodic AF on an elec-
trocardiogram, or transient AF (<24 hours) on a 24-hour
ambulatory electrocardiographic recording. 4) patients
with MCAO due to non-atherosclerotic etiology such as
vasculitis, vasospasm, dissection, aneurysm, basilar men-
ingitis, or Moyamoya disease, 5) patients with recanali-
zation of the occluded MCA after endovascular therapy,
6) and patients who presented with cancer, severe liver
disease, renal failure, or hematological disease.
In this study, all patients were performed MRA. One
hundred twenty-eight patients were performed DSA.
The magnetic resonance imaging was performed with a
1.5-T superconductive magnetic resonance system, and
all of the MRA examinations were obtained using three-
dimensional (3D) gadolinium (Gd)-enhanced technique.
A DSA was performed in all patients in whom MCA oc-
clusion was suspected from the MRA. The DSA were
performed after the vital signs were stabilized. The loca-
tion and severity of the stenosis was determined using
an MRA or DSA and the Warfarin-Aspirin Symptomatic
Intracranial Disease (WASID) trial criteria in all of the
patients [8,13]. The absence of distal filling of the MCA
on MRA or DSA could be regarded as MCA occlusion
[14]. The vessels with >50% stenosis or occlusions pres-
ence were categorized as intracranial stenosis. By defin-
ition, patients with “flow gaps” were considered to havean AIS (defined as 50% to 99% stenosis) [11]. If there
was more than one intracranial disease, the most severe
degree of stenosis was measured. According to the AIS,
all of the patients were assigned to one of two groups:
MCAO or MCAO-AIS group. The cerebrovascular ves-
sels were assessed by two experienced investigators who
used either an MRA or DSA at the patient’s entry into
the study and at each follow-up visit and who were
blinded to the other’s findings. Patients were excluded if
the MCA occlusion was caused by dissection or radi-
ation therapy.
This study was approved by the ethics committee of
Jinling Hospital, and written informed consent was ob-
tained from all patients.
Clinical backgrounds and characteristics
We reviewed the patients’ baseline demographic factors
and the medical records. The main risk factors for MCAO
were also recorded, such as hypertension (use of antihy-
pertensive agents, systolic blood pressure >140 mmHg or
diastolic blood pressure >90 mmHg before or at least
2 weeks after the stroke’s onset), diabetes mellitus (use of
hypoglycemic agents, a fasting blood glucose >7.0 mmol/L
or a postprandial blood glucose after 2 h >11.1 mmol/L),
hyperlipidemia (use of antihyperlipidemic medication, or a
total serum cholesterol level > 6.0 mmol/L or LDL choles-
terol concentration 3.63 mmol/l), a history of coronary
heart disease, cigarette smoking (at least 10 cigarettes per
day during the past 5 years or more), and alcohol intake
(consumed regularly more than 300 g alcohol/week). Pre-
vious use of antiplatelet agents, anticoagulants, or statins
was also evaluated.
Follow-up
We followed the patients who survived the acute phase
of stroke discharged after 1, 3, 6, 12 months by inter-
views or telephone to determine whether any events had
occurred. Asymptomatic patients had subsequent yearly
follow-up visits. The patients were asked whether they
had experienced any sudden episode of weakness, blind-
ness, numbness, speech difficulty and any other new
symptoms and documented in Nanjing Stroke Registry
Program. If a stroke was suspected, the patients were in-
vited to our Neurology Clinic and were evaluated by
study neurologists who were blinded to the treatment
assignment and also underwent brain computerized
tomography (CT) or magnetic resonance imaging (MRI).
The interviewers were blinded to the patient’s group al-
location. The composite outcome of the stroke recur-
rence or any-cause death was evaluated during the
follow-up period to elucidate the long-term prognosis of
symptomatic MCAO patients.
An ischemic stroke was defined as a new focal neuro-
logical deficit of sudden onset ≥ 24 hours in duration
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aging. An ipsilateral stroke was considered to have oc-
curred in the same location of the symptomatic artery
when the neurological signs correlated with a new in-
farct on a CT or MRI in an area of the brain supplied by
that artery.
Statistical analysis
The statistical analysis was performed with SPSS version
13.0 software (Chicago, Illinois, USA). A chi-square or
Fisher’s exact test was used to compare the rate and pro-
portions of the discrete variables, and Student’s-t tests
were performed for the continuous variables. We used
the Cox proportional hazards models for the univariate
and multivariate analyses to identify the potential factors
associated with stroke recurrence or any-cause death. A
Kaplan-Meier curve was generated for the cumulative
probabilities of stroke recurrence and the composite
outcome, and the two groups (MCAO and MCAO-AIS)
were compared using the log-rank test. The patients
who were lost to follow-up were censored at the last
contact date in the analysis. The results were expressed
as the adjusted odds ratio (OR) and corresponding 95%
confidence intervals (95% CI). For all statistical tests,
values are 2-sided and p < 0.05 was considered to indi-
cate statistically significant differences.
Results
During the study, 3460 patients were enrolled from the
databank. Three hundreds and six (8.8%) patients were
recruited, all of them were first-ever stroke. Among
them, 35 patients died in the acute phase (11.4%) and,
39 patients (14.39%) underwent a surgical revasculariza-
tion procedure and were excluded. Therefore, we in-
cluded 232 first-ever stroke patients with complete
occlusion of the MCA in this study, and followed them
for an average of 17.65 ± 10.81 months (range, 1 to
39 months). Seven (3.02%) patients were lost during the
follow-up. The mean age was 57.68 ± 9.50 years, andTable 1 Comparison of demographic and clinical characterist
MCAO (n = 84)
Age, years 55.58 ± 9.48
Gender (Male) 59 (71.1%)
Hypertension (Yes) 39 (47.0%)
Diabetes mellitus (Yes) 18 (21.7%)
Hyperlipidemia (Yes) 18(21.7%)
Coronary artery disease (Yes) 17 (20.5%)
Smoking (Yes) 42 (50.6%)
Drinks alcohol (Yes) 27 (32.5%)
Composite outcome (Yes) 5 (6.0%)
Notes: MCAO, middle cerebral artery occlusion. MCAO-AIS, middle cerebral artery o69% of the patients were male. All of the patients were
continuously treated with both antiplatelet agents and
statins if the patients had not any adverse events. Eighty-
four patients were well controlled their lipid level (total
cholesterol (TC) <3.6 mmol/L, LDL-C < 1.8 mmol/l).
The distribution of the baseline characteristics and the
composite outcome (stroke recurrence or any-cause death)
is listed in Table 1.
The total patients in MCAO-AIS is 149 (64.22%). The
patients in MCAO-AIS were more likely to have high
blood pressure at enrollment (65.1% versus 47.0%, p =
0.007), and a poor composite outcome (20.1% versus 6.0%,
p = 0.004) than their counterparts MCAO (Table 1).
Rate of stroke recurrence or any-cause death
During the follow-up period, 11 (4.74%) of the 232 pa-
tients died (three women (1.29%) and eight men (3.45%)).
Three patients (1.29%) died from the initial stroke, two
(0.86%) died from a recurrent stroke, one (0.43%) died
from cardiovascular disease, and five (2.16%) died from
pulmonary causes (pneumonia or pulmonary embolisms).
We documented 35 (15.09%) composite outcomes dur-
ing the observation. The Kaplan-Meier curves showed that
a significantly lower proportion of patients in the MCAO-
AIS group survived without a composite outcome when
compared with the MCAO group (79.90% vs. 94.00%,
p = 0.009, Figure 1A). The cumulative stroke recurrence
or any-cause death rate was 4.80% at one year, 21.30% at
two years, and 25.40% at three years in the MCAO-AIS
group, compared with 4.5%, 6.60%, and 10.80%, respect-
ively, in the MCAO group.
Risk factors of recurrent stroke or death
The variables that were potentially associated with the
MCAO prognosis are listed in Table 2. The univariate ana-
lysis revealed that hypertension (OR = 3.715, 95% CI 1.541
to 8.958), diabetes mellitus (OR = 3.614, 95% CI 1.858 to
7.032), and the coexistence of AIS (OR = 3.265, 95% CI
1.267 to 8.416) were associated with the occurrence ofics between MCAO and MCAO-AIS
MCAO-AIS (n = 148) P value









cclusion with concomitant intracranial arterial disease.
Figure 1 Comparison of the survival curves estimated with the Kaplan-Meier model between the MCAO and MCAO-AIS groups (using the
log-rank test), showing the cumulative event-free proportion of the total composite outcome (A) and ipsilateral ischemic stroke recurrence
(B) during the observation period.
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as hypercholesterolemia, smoking, and a family history of
stroke, were not found to be correlated with stroke occur-
rence or death. These variables were included in the multi-
variate analysis of the Cox proportional hazard model.
Then we found that the coexistence of AIS remained an
independent predictor of symptomatic MCAO progression
(OR = 3.426, 95% CI 1.261 to 9.308; p = 0.016). Moreover,
diabetes mellitus was related to the recurrence of both
overall (p < 0.01) and ipsilateral ischemic vascular events
(p < 0.01).
Considering that the presence of MCAO-AIS showed
a significant difference for the composite outcomes (p =
0.016), we further analyzed this subgroup, as shown in
Table 3. Hypertension (p = 0.016), diabetes mellitus (p =
0.007), and coronary artery disease (p = 0.033) were sig-
nificantly associated with stroke recurrences or any-
cause death in the univariate analysis. These 3 variablesTable 2 Potential risk factors of cerebrovascular events
and any-cause death of patients with symptomatic MCAO
Risk factors Univariate OR Multivariate OR
(P value) (P value)
Age, years 1.010 (0.573) 0.980 (0.337)
Gender (Male) 0.562 (0.092) 0.444 (0.041)
Hypertension 3.715 (0.003) 2.465 (0.062)
Diabetes mellitus 3.614 (0.001) 2.842 (0.003)
Hyperlipidemia 1.710 (0.168) 2.065 (0.075)
Coronary artery disease 1.927 (0.080) 1.664 (0.186)
Smoking 1.067 (0.848) 1.427 (0.405)
Drinks alcohol 0.985 (0.967) 1.277 (0.599)
Coexisting AIS 3.265 (0.014) 3.426 (0.016)
Notes: MCAO, middle cerebral artery occlusion. OR, odds ratio.were included in the logistic regression model. Diabetes
mellitus was the only factor independently associated
with the recurrence of cerebral vascular events or any-
cause death during the follow-up (OR = 2.282, 95% CI
1.089 to 4.782; p = 0.029). The Kaplan-Meier curves
showed that a significantly lower proportion of patients
presenting with AIS survived free of a stroke recurrence
or any-cause death compared with the MCAO group
(Figure 1A). However, we refrained from further multi-
variable analysis of the patients without concomitant
AIS, because of the relatively small number of composite
outcomes.
Risk of an ipsilateral cerebral ischemic event
A new ischemic vascular event was noted in 22 patients
(13 strokes and 9 TIAs), resulting in an overall annual
rate of 6.45%. Seventeen events (77.27%) occurred in the
location of the symptomatic occlusive MCA. StrokesTable 3 Univariate and Multivariate Model of outcome
for symptomatic MCAO-AIS
Risk factors Univariate OR Multivariate OR
(P value) (P value)
Age, years 0.996 (0.854) 0.978 (0.314)
Gender (Male) 0.573 (0.131) 0.465 (0.082)
Hypertension 3.635 (0.016) 3.011 (0.051)
Diabetes mellitus 2.685 (0.007) 2.282 (0.029)
Hyperlipidemia 1.773 (0.188) 2.102 (0.102)
Coronary artery disease 2.349 (0.033) 1.792 (0.157)
Smoking 0.897 (0.768) 1.220 (0.688)
Drinks alcohol 0.976 (0.953) 1.443 (0.486)
MCAO-AIS, middle cerebral artery occlusion with concomitant intracranial
arterial disease. OR, odds ratio.
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(22.73%) of the 22 patients. Of these 17 ipsilateral events,
11 were ischemic strokes (annual rate 3.22%) and 6 were
TIAs (annual rate 1.76%). Among the patients in MCAO-
AIS, 14 subjects experienced ipsilateral cerebrovascular
events (10 strokes, 4 TIAs), with an occurrence rate of
7.00% in the first year, 10.2% in the second year, and
14.80% in the third year, compared with 3.30%, 5.40%, and
5.40% in the MCAO group respectively (1 stroke, 2 TIAs).
The patients in MCAO-AIS tended to have ipsilateral is-
chemic strokes more frequently than those without AIS
(9.40% vs. 3.60%), but this trend was not statistically sig-
nificant in the Kaplan-Meier plots (p = 0.131) (Figure 1B).
Both hypertension (p = 0.017) and diabetes mellitus (p =
0.000) were significantly associated with ipsilateral ische-
mic vascular event in the univariate analysis (Table 4). Both
of these variables were included in the logistic regression
model, and diabetes mellitus remained an independent
predictor for the occurrence of ipsilateral ischemic strokes
and TIAs (OR = 5.671, 95% CI 1.926 to 16.694; p = 0.002).
Discussion
This follow-up study provides evidence about the dy-
namic nature of symptomatic MCA atherosclerotic oc-
clusive disease with coexisting AIS. We found that the
prevalence of concomitant AIS (50% to 99%) in our co-
hort of patients with symptomatic MCAO was high
(63.79%). Our data suggests that the rate of stroke recur-
rence or any-cause death in MCAO-AIS is much higher
than in MCAO (p < 0.01).
Despite the widespread availability of valid diagnostic
methods, there is little reported in the literature on the
prognostic markers following an MCA occlusion. Our
data demonstrated that diabetes, the systolic blood pres-
sure at enrollment, and MCAO-AIS were statistically
significant, modifiable risk factors for the prognosis of
patients with MCAO. Diabetes mellitus is a well-knownTable 4 Potential predictors of ipsilateral stroke
recurrence
Risk factors Univariate OR Multivariate OR
(P value) (P value)
Age, years 1.027 (0.321) 0.995 (0.880)
Gender (Male) 0.595 (0.292) 0.358 (0.078)
Hypertension 6.047 (0.017) 3.318 (0.135)
Diabetes mellitus 7.427 (0.000) 5.671 (0.002)
Hyperlipidemia 1.651 (0.383) 2.087 (0.248)
Coronary artery disease 2.698 (0.051) 2.407 (0.101)
Smoking 1.610 (0.334) 2.007 (0.253)
Drinks alcohol 1.317 (0.588) 1.522 (0.524)
Coexisting AIS 2.523 (0.146) 2.948 (0.132)
Notes: AIS, intracranial arterial disease. OR, odds ratio.risk factor for both small and large vessel diseases. Previ-
ous studies have identified diabetes mellitus as a risk fac-
tor for recurrent vascular events or death in patients
with predominantly intracranial atherosclerosis [9,10].
We also identified the presence of diabetes mellitus as a
potential independent potential predictor of the long-
term outcome, stroke recurrence, or any-cause death.
The poor control of blood pressure appeared to be asso-
ciated with a higher risk of a subsequent stroke [15]. In
addition, the prevalence of coexisting asymptomatic
intracranial stenosis in our cohort of patients with
MCAO was 63.79% and was an independent risk factor
for the prognosis of MCAO stroke patients. Collaterals
also should be considered in the MCAO-AIS patients, as
they can be observed to varying extents in intracranial
atherosclerosis, whereas the presence of any collateral in
moderate stenosis patients was an ominous predictor of
stroke [16]. Individuals with robust collaterals may be at
risk for stroke, although to a lesser extent than those
without collaterals. Arenillas and his colleagues reported
that the number of coexisting asymptomatic stenoses
showed a trend toward a higher recurrence rate [5].
Others have reported that several variables, such as se-
vere stenosis, stroke symptoms, and being female, were
predictors of a subsequent stroke in the location of the
stenotic artery among patients with AIS [4]. However,
there is relatively little information on the relationship
between the risk factors and the recurrence of vascular
events in patients with an intracranial artery stenosis or
occlusion, which remains to be further studied.
Although the mechanisms of ischemic stroke in intra-
cranial atherosclerosis remain largely unexplored, the di-
minished flow beyond a stenosis may cause a stroke due
to hypoperfusion or the impaired washout of the throm-
boemboli. Arterial occlusion due to the progressive ath-
erosclerotic stenosis of an intracranial segment may
allow robust collaterals to develop over time, although
the relationship of these collaterals to the cerebral blood
flow and clinical symptomatology remains unclear. Col-
laterals could radically decrease the risk of recurrent
stroke in traditionally defined chronic disorders such as
intracranial atherosclerosis and moyamoya disease.
MCAO-AIS indicate poor collaterals, and the reduced
antegrade of the forward flow beyond the lesion may
cause a stroke due to hypoperfusion [17]. The cases en-
rolled in the WASID trial were symptomatic with re-
spect to a particular arterial lesion, but the role of
multifocal disease may provide an opportunity to correl-
ate collaterals with concomitant asymptomatic lesions,
as well as with the symptomatic intracranial atheroscler-
otic lesion [11]. Therefore, collaterals and the functional
demonstration of flow impairment may be more inform-
ative than the isolated anatomical measures of maximal
stenosis or length. Moreover, decreased perfusion reduces
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presence of MCAO-AIS may indicate that the arterial ath-
erosclerosis is more severe and extensive, identifying an
unstable, evolving plaque [16]. Then, the ischemia may be
incited due to artery-to-artery emboli. However, our mea-
sures of the maximal degree of stenosis are only rudimen-
tary measures of the plaque architecture that influences
the hemodynamic parameters. The lesion length, luminal
irregularity, vessel tortuosity, and other factors beyond
these parameters may cause hemodynamic impairment or
thromboembolic potential.
The annual rate of cerebrovascular events in our study
was 6.45%, which was much lower than in the WASID
trial [19]. The mechanism of the low stroke risk in the
patients surviving occlusions in the M1 segment of the
MCA is uncertain, and may be attributable to the fol-
lowing. First, nearly all of the included subjects used an-
tiplatelet therapy and statins. Previous studies have
demonstrated that statins provide beneficial effects for
the long-term functional outcomes in cerebral ischemia
[20]. The pleiotropic effects of statins, which are beyond
lipid lowering, include the modification of endothelial
function, inflammatory responses, plaque vulnerability,
and thrombus formation [21,22]. Second, our subjects
were survivors of MCAO, which suggests that they may
have good collaterals. Collaterals have had a dramatic
role in averting stroke when the degree of arterial sten-
osis was severe [16]. A study demonstrated that patients
with a decreased rCBF and rCVR resulting from an ICA
or MCA occlusion have a higher risk of an ipsilateral or
total ischemic stroke than those without such decreases.
Although some of the patients with poor collaterals or
the absence of collaterals died during the acute phases
of their strokes and were excluded from this study, some
of the patients with poor collaterals survived the acute
phase of their strokes. Third, the MCAO patients were
diagnosed by an MRA in previous studies, which may
include severe stenosis of the MCA. The risk of a
thrombus artery-to-artery embolism was higher in the
patients with severe stenosis of the MCA compared with
the MCA occlusion subjects. However, the cerebral an-
terior circulation is subject to more embolic infarctions
and fewer incidents of severe intracranial atherosclerosis
than the posterior/vertebrobasilar circulation [23].
There are some limitations in the present study. First,
our study was a single-center study. The small number
of cases and numerous risk factors may have led to the
underestimation of the risk of MCAO due to a lack of
statistical power. Future large- scale community or
population-based studies are needed. Second, a conven-
tional angiography was not performed in all of the
MCAO patients because of its invasiveness, and the
MRA does not have sufficient sensitivity and specificity
values. Thus, the study may suffer from a selection bias.Third, as some of the cases were followed through tele-
phone interviews for stroke recurrences, minor strokes
may not have been observed.
Conclusion
In conclusion, we demonstrated that the prevalence of
concomitant AIS in our cohort of subjects with symptom-
atic MCAO was high and that the MCAO-AIS was an in-
dependent prognosis factor. The current results indicate
that symptomatic MCAO patients with the presence of si-
lent AIS may require intracranial angioplasty and stenting
or intensive medical management to prevent recurrent
strokes. According to the results of the Stenting vs. Ag-
gressive Medical Management for Preventing Recurrent
Stroke in Intracranial Stenosis (SAMMPRIS) trial, aggres-
sive medical therapy was superior to percutaneous trans-
luminal angioplasty and stenting with the use of the
Wingspan stent system [24]. Therefore, we suggest that
symptomatic MCAO-AIS patients should receive aggres-
sive medical management, or stenting for severe stenosis
if necessary [25]. However, the results of such manage-
ment remain to be determined in future prospective trials.
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